16-GBM-12-BE (BXQ-350-AA) Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients with Advanced Solid Tumors and Glioblastoma Multiforme